KORU Medical Systems, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by KORU Medical Systems, Inc. (KRMD) on August 15, 2024. The filing discloses the approval and implementation of a new Long-Term Incentive Program (LTIP) by the Compensation Committee of the Board of Directors. The program is designed to incentivize the retention and performance of executive officers and other employees through annual equity-based awards granted under the Company's 2024 Omnibus Equity Incentive Plan.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the current or prior periods. The document focuses exclusively on executive compensation arrangements and equity grant details.
Material Changes and Compensation Details
On August 15, 2024, the Company approved LTIP awards for four executive officers. The awards consist of Restricted Stock Units (RSUs), Performance Stock Units (PSUs), and Nonqualified Stock Options. The specific grants are as follows:
- Linda Tharby (President and CEO): 63,872 RSUs, 127,660 Target PSUs, and 140,950 Options.
- Thomas Adams (CFO): 21,617 RSUs, 21,617 Target PSUs, and 47,722 Options.
- Kenneth Miller (CCO): 23,574 RSUs, 23,574 Target PSUs, and 52,008 Options.
- Christopher Pazdan (COO): 20,255 RSUs, 20,255 Target PSUs, and 44,721 Options.
Terms and Conditions:
- Options: Exercise price is $2.33 per share (based on the arithmetic mean of high/low prices on the last trading day prior to grant). Options expire ten years after the grant date.
- Vesting Schedule: RSUs and Options vest in four equal tranches (25% annually) starting March 15, 2025, subject to continued employment.
- PSU Performance Criteria: PSUs vest based on the Company's annual revenue for the fiscal year ended December 31, 2026. Vesting ranges from 0% to 150% of the target. A payout modifier (0.5x to 1.5x) applies based on the average stock price for the 20 days prior to December 31, 2026.
- Change in Control: Unvested RSUs fully vest upon a Change in Control. If a Change in Control occurs prior to December 31, 2026, PSUs vest at 100% of the target with a stock price modifier.
Additional Compensation Change: On August 16, 2024, the Committee approved a base salary increase for Kenneth Miller (CCO) from $360,000 to $385,000 (an increase of $25,000), effective August 18, 2024. His bonus potential was also increased to up to 60% of his annual base salary.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard terms of the equity awards. The primary contingency noted is the performance-based nature of the PSUs, which are contingent on achieving specific revenue targets for the fiscal year ending December 31, 2026, and the Company's stock price performance.
Key Facts for Investor Verification
- Verify the total number of shares reserved in the 2024 Omnibus Equity Incentive Plan to assess dilution impact from these new grants.
- Confirm the specific revenue targets required to achieve the 100% and 150% vesting levels for the PSUs, as these are not explicitly detailed in this summary text.
- Monitor the Company's stock price performance relative to the $2.33 option exercise price and the future stock price modifier for PSUs.
- Review the full text of the Long-Term Incentive Program (Exhibit 10.1) for detailed definitions of "Change in Control" and specific performance metrics.